SANOFI-AVENTIS (EPA:SAN) | Finanzwire

Basculer en Français

11118	Companies
244805	Keywords
172884	Articles
131993	Press releases

Home
Companies
SANOFI-AVENTIS

PRESS RELEASE

published on 09/24/2025 at 07:05, 1 year ago

Press Release: Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation
Sanofi commits $625 million to Sanofi Ventures to boost biotech and digital health investments. Focus on immunology, rare diseases, neurology, vaccines

Digital Health Investment Biotech Ventures Sanofi
PRESS RELEASE

published on 09/24/2025 at 07:00, 1 year ago

Press release: Availability of the Q3 2025 Aide mémoire
Sanofi announces availability of Q3 2025 Aide mémoire for financial modeling purposes. Document covers non-comparable items, foreign currency impact, and share count

Investors Sanofi Financial Modeling Aide Mémoire Q3 2025
BRIEF

published on 09/23/2025 at 07:05, 1 year ago

Sanofi's SAR446268 Therapy Advances in the United States

Gene Therapy Sanofi SAR446268 FDA Admission Myotonic Dystrophy
PRESS RELEASE

published on 09/23/2025 at 07:00, 1 year ago

Press Release: Sanofi’s SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1
Sanofi's SAR446268 granted US fast track designation for non-congenital myotonic dystrophy type 1. AAV gene therapy aims to silence DMPK expression, addressing symptoms and filling unmet need

AAV Gene Therapy Sanofi Fast Track Designation SAR446268 Myotonic Dystrophy Type 1
BRIEF

published on 09/17/2025 at 07:05, 1 year ago

Sanofi's Brivekimig Shows Promise in Hidradenitis Suppurativa Treatment

Brivekimig Hidradenitis Suppurativa Phase 2a Study Nanobody Technology Immune-mediated Diseases
PRESS RELEASE

published on 09/17/2025 at 07:00, 1 year ago

Press Release: EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study
Sanofi's brivekimig shows positive results in phase 2a study for hidradenitis suppurativa, presenting clinically meaningful improvements in primary and secondary endpoints in biologic-naïve patients

Sanofi Brivekimig Hidradenitis Suppurativa Phase 2a Study Immune-mediated Diseases
PRESS RELEASE

published on 09/15/2025 at 18:30, 1 year ago

Sanofi: Disclosure of trading in own shares
BRIEF

published on 09/12/2025 at 18:35, 1 year ago

Sanofi Publishes Voting Rights Data for August 2025

Voting Rights Actions Financial Markets Sanofi August 2025
PRESS RELEASE

published on 09/12/2025 at 18:30, 1 year ago

Sanofi: Information concerning the total number of voting rights and shares - August 2025
Sanofi discloses total number of voting rights and shares as per French regulations. Details available on Sanofi's website

Voting Rights Shares French Regulations Disclosure Sanofi
BRIEF

published on 09/11/2025 at 07:05, 1 year ago

Sanofi Obtains Fast Track Designation for SAR402663 in the United States

FDA Gene Therapy Sanofi Fast Track AMD

Accesswire

Published on 10/03/2026 at 02:35, 19 hours 7 minutes ago

Jaguar Health Announces a Special Stock Dividend
Published on 10/02/2026 at 17:45, 1 day 3 hours ago

Sparton Provides Status Update
Published on 10/02/2026 at 13:50, 1 day 7 hours ago

AI/ML Innovations Appoints Lynn Chapman as Chief Financial Officer and Announces Share Issuance for Debt Settlement
Published on 10/02/2026 at 13:00, 1 day 8 hours ago

Evergold Drills 4.9 m of 7.70 g/t Au and 186.0 g/t Ag Within 13.5 Metres of 2.84 g/t Au and 127.6 g/t Ag in First 2026 Drill Holes at Golden Lion
Published on 10/02/2026 at 13:00, 1 day 8 hours ago

Alaska Energy Metals Appoints Independent Director, Thomas Benson

View all ACCESSWIRE

EQS Group

Published on 10/03/2026 at 15:45, 5 hours 57 minutes ago

Huawei Highlights Continuous Innovation, Securing Competitive Edge Through Technological Breakthroughs
Published on 10/02/2026 at 23:55, 21 hours 47 minutes ago

IS SKINCARE GETTING TOO COMPLICATED? CERAVE MAKES THE CASE FOR SAFETY, EFFICACY AND SIMPLICITY
Published on 10/02/2026 at 20:23, 1 day 1 hour ago

EQS-Adhoc: Pentixapharm Holding AG: Bafin concludes financial reporting review of the 2024 consolidated financial statements with an error finding
Published on 10/02/2026 at 19:46, 1 day 1 hour ago

innoscripta SE: Update on the Tax Authorities’ Investigation – Business Operations Continue as Usual – Full Transparency Assured – Invitation to Shareholders for an In-Person Product Presentation
Published on 10/02/2026 at 18:00, 1 day 3 hours ago

EQS-Adhoc: AMUNDI PHYSICAL GOLD ETC (the “ETC”): Release of the first Supplemental Base Prospectus (the “Supplemental”)

Les Echos

Published on 10/02/2026 at 17:45, 1 day 3 hours ago

Information concerning the total number of voting rights and shares 2026 09 30
Published on 10/02/2026 at 17:30, 1 day 4 hours ago

Aéroports de Paris SA - 2027 Financial Calendar
Published on 10/01/2026 at 19:00, 2 days 2 hours ago

AMA CORP PLC reduces its cost base while preserving XpertEye’s key functions
Published on 10/01/2026 at 18:40, 2 days 3 hours ago

Monthly disclosure of the total number of shares and voting rights - September 2026
Published on 10/01/2026 at 18:05, 2 days 3 hours ago

Covivio - Information on total number of voting rights and share capital

View all LES ECHOS COMFI WIRE